Oramed Completes Patient Enrollment in Pivotal Phase 3 Oral Insulin Study ORA-D-013-1
ORMD-0801 positioned to potentially be the first FDA approved oral insulin for the treatment of diabetes Completed enrollment of 710 patients for the Phase 3 ORA-D-013-1 study Top line data expected in January 2023 NEW YORK , May 3, 2022 /PRNewswire/ — Oramed Pharmaceuticals Inc.
